Arcutis Announces Pricing of $100 Million Public Offering
19 oct. 2023 23h45 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis Announces Proposed Public Offering
19 oct. 2023 16h04 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations...
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
13 oct. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
25 sept. 2023 09h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
19 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children...
Arcutis to Present at Upcoming Investor Conference
05 sept. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
31 août 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Company shows advancement toward improving patient care, access and affordability, social capital, drug safety, sustainability, and ethical business practices WESTLAKE VILLAGE, Calif., Aug. 31, 2023...
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
29 août 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above...
Arcutis Appoints Interim Chief Financial Officer (CFO)
18 août 2023 16h30 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
08 août 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...